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ABSTRACT  Glucocorticoids	(GCs)	play	a	key	role	in	regulating	lipid	metabolism.	However,	various	studies	have	found	conflicting	results	on	whether	they	are	predominantly	lipolytic	or	lipogenic,	likely	due	to	differences	in	models,	exposure	times	and	which	tissues	were	being	examined[1].	While	GCs	are	produced	endogenously	in	response	to	stress,	they	are	also	potent	anti-inflammatory	agents	and	often	consumed	exogenously	as	a	treatment	for	inflammatory	conditions[2].	For	this	reason,	it	is	necessary	that	we	have	a	clear	understanding	of	their	physiological	role	in	the	regulation	of	metabolism.	Despite	this,	little	is	known	about	their	immediate	response,	especially	in	conjunction	with	exercise.	For	this	study,	Wistar	rats	were	randomly	divided	into	four	groups:	sedentary	+	vehicle	(SV),	sedentary	+	corticosterone	(SC),	exercise	+	vehicle	(EV),	and	exercise	+	corticosterone	(EC).	All	animals	received	an	i.p.	injection	of	their	treatment	(t	=	-15	min)	and	exercisers	performed	a	45-minute	exercise	on	metabolic	treadmills.	All	tissue	collection	occurred	at	t	=	+45	min.	SC	animals	had	more	fluctuation	in	their	respiratory	exchange	ratio	(RER)	over	time	compared	to	SV.	In	exercise	groups,	no	differences	in	RER	were	observed.	Non-esterified	fatty	acid	(NEFA)	levels	were	not	significantly	different	between	groups	after	one	hour	and	lipolytic	enzyme	activity	analyses	indicated	that	SC	animals	had	enhanced	enzyme	activity	compared	to	EC,	but	were	not	different	from	SV	(p	=	0.047).	Analyses	indicate	that	GCs	may	acutely	induce	lipolysis	when	sedentary,	but	not	in	an	exercise	state. 	
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1.0 INTRODUCTION  
 Glucocorticoids (GCs) are hormones released from the adrenal glands and one of 
their predominant roles is to provide fuels to be used as energy in a state of stress[3]. 
Their release is regulated by the hypothalamic-adrenal-pituitary (HPA) axis and rises 
significantly with a stress response, although, they are also released at a low 
concentration throughout the day in a diurnal pattern where they are highest before 
waking up and lowest going to bed[4]. In addition to their endogenous release, they are 
also potent anti-inflammatory agents and are often supplemented to treat various 
conditions. Since the 1950s, GCs have been a predominant treatment for inflammation, 
either for an acute injury, or for chronic conditions including arthritis or asthma[5]. 
However, the rise in their use has shed light on some of their less desirable metabolic 
consequences, specifically when used over a chronic period. Various rodent models have 
also revealed that hypercortisolemia results in adiposity and associated comorbidities, 
including fatty liver, hepatic steatosis, elevated fasting glycaemia and insulin 
resistance[6,7]. These effects are also seen in Cushing’s syndrome (CS), a condition of 
chronic hypercortisolism, often caused by enhanced stimulation of the HPA axis[8,9]. 
Despite their ability to induce adiposity, GCs enhance lipolysis, the breakdown of TAGs 
to NEFAs and glycerol, through increasing the transcription of various lipolytic enzymes 
(ATGL and HSL), as observed in various cell culture and rodent models[10,11]. Most of 
these studies have examined the chronic adaptations, but their immediate actions have not 
been studied extensively in vivo. Interestingly, cell culture models using 3T3-L1 cells 
have found that a very acute exposure (1 hour) to GCs exerts the opposite effects on lipid 
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metabolism, impairing lipolytic actions[12]. This impairment was further increased as 
concentration of GCs was increased. 
Aerobic exercise is also considered a pro-lipolytic trigger, and being a 
physiological stressor, it induces a rise in catecholamines, immediately followed by an 
increase in GCs. It is often assumed that during exercise, GCs are involved in increasing 
the mobilization of fuels, specifically glucose and non-esterified fatty acids (NEFAs)[13], 
yet the acute interaction between elevated GCs and aerobic exercise on metabolism has 
yet to be thoroughly examined. In order to gain a better understanding of the immediate 
actions of GC on metabolism in vivo, and a better understanding of the physiological 
lipid response with exercise, we designed a model that examines the acute (1 hour) 
effects of GCs on lipid metabolism in both a resting and exercising state to get a better 
understanding of the specific actions that would occur with a stress response or a one 
time treatment with glucocorticoids. 
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2.0 LITERATURE REVIEW  
2.1	ENERGY	SUBSTRATE	METABOLISM	
i. Overview of Energy Substrate Metabolism 
Metabolism comprises all of the chemical processes within a cell, tissue or 
organism that are required to sustain life. These processes are tightly controlled with 
various regulators and feedback signals in order to maintain cellular homeostasis[14]. 
Additionally, cells have the ability to respond to ever-changing environments and adapt 
to a number of factors including lifestyle (diet, physical activity, stress), environmental 
(temperature, altitude), age, gender and genetic components[15–21]. 
Although there are many aspects to consider when studying metabolism, energy 
substrate metabolism focuses on utilizing fuels for energy, specifically looking at the 3 
major macronutrients: carbohydrates (CHOs), lipids and proteins. It is important to note 
that in normal physiological conditions, proteins contribute a negligible amount to 
cellular energy. For this reason, this review will be predominantly focused on glucose 
and lipid metabolism, with special attention being placed on lipids. All tissues in the body 
require energy to function, but the three major tissues that influence fuel oxidation are: 
skeletal muscle (which has the greatest influence on fuel selection), liver, and adipose 
tissue. Dysregulation in any of these tissues results in significant metabolic 
consequences. 
ii. Carbohydrate Metabolism 
Due to the increasing prevalence of insulin resistance and type 2 diabetes, a lot of 
research has been focused on glucose metabolism and regulatory factors. Glucose 
metabolism is predominantly regulated through insulin signalling, which increases 
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glucose uptake into tissues[22]. It does this through inducing the translocation of the 
glucose transporter, GLUT4, to the cell membrane to allow an influx of glucose into the 
cell[23]. Additionally, GLUT4 translocation may occur through an insulin-independent 
pathway when stimulated by muscle contraction, such as with exercise[24]. Once glucose 
enters the cell, it may be stored as glycogen; otherwise, it may undergo glycolysis and be 
converted to pyruvate. From here, it may be oxidized and used as a fuel for energy, either 
through aerobic respiration in the mitochondria, or anaerobically in the cytosol. Unlike 
the other major macronutrients, the body does not have a very large storage capacity for 
CHOs and its metabolism is regulated in a tissue-specific manner[25]. If systemic levels 
are elevated, the pancreas will release insulin to facilitate glucose uptake in tissues and 
the liver will convert excess glucose into glycogen until it needs to be utilized again[26]. 
Conversely, if circulating levels are low, the pancreas will release glucagon to signal the 
liver to convert glycogen into glucose. 
iii. Lipid Metabolism 
Adipose tissue is a functional metabolic tissue that affects thermogenesis, energy 
storage, metabolic regulation, mitochondrial biogenesis and immune system stimulation 
through the release of cytokines[27,28]. It is influenced by nutrition, satiety level, 
neuroendocrine factors and the circadian rhythm[29,30]. There are two types of adipose 
tissue, brown and white. Brown adipose tissue’s primary function is to convert energy 
into heat[27,31]. White adipose tissue (WAT) is more abundant in adults and serves as a 
major energy reserve in mammals[32]. WAT is maintained through a balance between 
two processes, lipogenesis and lipolysis. Lipogenesis is the process of fatty acid synthesis 
in which triacylglycerol (TAG) is stored to be utilized later[33]. This process is favoured 
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when there is a positive energy balance, such as in a post-prandial state when insulin (a 
potent lipogenic agent) is high, or in a resting state when energy expenditure is low[34]. 
One way in which insulin influences lipogenesis is by increasing lipoprotein lipase 
(LPL), an enzyme involved in up-taking NEFAs into the cell to either be stored or 
oxidized. At the same time, insulin also inhibits lipolysis by reducing the activity of 
various lipolytic enzymes within the adipocytes themselves.   
Lipolysis is the contrary process; it involves the hydrolysis of TAG to allow them to 
be mobilized and released into the blood as NEFAs[32]. In addition to glucose, NEFAs 
are a major fuel source that may be oxidized and used for energy via mitochondrial 
oxidative metabolism[34]. For this reason, lipolysis is dominant when there is a deficit in 
energy, such as in a fasted state or during exercise, when the body requires additional 
fuel.   
Healthy individuals are able to balance these processes and maintain a healthy 
amount of body fat. However, for various reasons, metabolic deregulation sometimes 
occurs and may cause excessive accumulation of adipose tissue and an increases risk of 
metabolic aberrations and associated comorbidities[29]. 
iv. The Lipolytic Pathway 
Lipolysis is regulated through many factors, but the greatest known moderators of 
the process are catecholamines[35] (Fig. 1.1). Circulating catecholamines, epinephrine 
(Epi) and norepinephrine (NE), bind to the β-adrenergic receptors (β-ARs) of adipocytes; 
this leads to the activation of adenylyl cyclase (AC) through interacting with the G-
stimulatory (Gs) coupled protein[36]. AC increases cyclic adenosine monophosphate 
(cAMP) production, which leads to protein kinase A (PKA) activation[36]. PKA has two 
		 6	
roles in promoting the lipolytic pathway, while simultaneously blocking the anti-lipolytic 
pathway. PKA activation inhibits insulin action by blocking phosphatidylinositol-3	kinase	(PI-3K)	activity,	which	ultimately	inhibits	the	anti-lipolytic	effects	of	 insulin	to	reduce	intracellular	cAMP	content[37]. In addition, PKA activation has two modes 
of action to directly promote lipolysis; it triggers the phosphorylation of both perilipin 
(PLINs) and hormone sensitive lipase (HSL)[38]. PLINs are a family of enzymes that 
suppress lipolysis in a basal state, yet facilitate PKA stimulated lipolysis[39,40]. PLINs 
are structural proteins that coat the lipid droplet and once phosphorylated, assist in 
translocating phosphorylated HSL from the cytosol to lipid droplets, where 
phosphorylated HSL can facilitate lipolysis[41]. Additionally, it has been suggested that 
PLIN may be involved in positive feedback of PKA to increase the activation and further 
stimulate lipolysis[40]. In addition to assisting in the translocation of phosphorylated 
HSL (pHSL), the phosphorylation of perilipin also frees comparative gene identification 
58 (CGI-58), a protein bound to perilipin. Once free, CGI-58 is able to activate adipose 
triglyceride lipase (ATGL) on the lipid droplet. ATGL, HSL, as well as 
monoacylglycerol lipase (MGL), are the primary lipases responsible for the breakdown of 
TAG to NEFAs in the lipid droplet (Fig. 1.2). The first step in the process involves 
ATGL, the rate-limiting enzyme, which converts TAG to diacylglycerol (DAG), 
releasing one NEFA in the process. From here, phosphorylated HSL converts DAG to 
monoacylglycerol (MAG), releasing an additional NEFA. Lastly, MGL cleaves MAG to 
be broken down into glycerol and one last NEFA[32]. The NEFAs and glycerol are then 
returned to the cytosol and are released back into circulation. Adipocyte fatty acid 
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binding protein (AFABP) shuttles the NEFAs out of the adipocyte and Aquaporin-7 
(AQP7) facilitates the release of glycerol into circulation.   
 
Figure 1.1, The lipolytic pathway within the adipocyte. Catecholamines 
(epinephrine or norepinephrine) act at the beta-adrenergic receptor (β-AR) to stimulate 
adenylyl cyclase (AC), which converts adenosine triphosphate (ATP) into cyclic 
adenosine monophosphate (cAMP). cAMP phosphorylates protein kinase A (PKA), 
which phosphorylates hormonse sensitive lipase (HSL) and perilipin (PLIN). PLIN 
translocates HSL to the lipid droplet. Within the lipid droplet, triacylglycerols (TAGs) are 
broken down into 3 Non-esterified fatty acids (NEFAs) + 1 glycerol. NEFAs leave the 
cell with the assistance of adipocyte fatty acid binding protein (AFABP) and glycerol is 
released by aquaporin-7 (AQP7).   
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Figure 1.2, Triacylglycerol breakdown within the lipid droplet. 
Triacylglycerol (TAG) is broken down into diacylglycerol (DAG) by adipose triglyceride 
lipase (ATGL). In this step, one non-esterified fatty acid (NEFA) is released. 
Phosphorylated-hormone sensitive lipase (pHSL) breaks down DAG into 
monoacylglycerol (MAG), releasing one NEFA in the process. Monoacylglycerol lipase 
(MGL) breaks down MAG to one NEFA + one glycerol.  
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v. Anti-Lipolytic Pathway 
The lipolytic pathway may also be inhibited by various hormones, most notably, 
insulin. When insulin binds to the insulin receptor (IR), it activates tyrosine kinases, 
which causes an interaction with insulin receptor substrates 1 and 2 (IRS-1, IRS-2). This 
leads to the phosphorylation of Pi-3K[42]. Pi-3K goes on to activate of phosphodiesterase 
3B (PDE-3B), an enzyme that catalyzes cAMP breakdown to 5' adenosine 
monophosphate (5’ AMP), limiting the amount of PKA phosphorylation, thereby 
inhibiting all the downstream actions in the lipolytic pathway. In addition, insulin is 
involved in the phosphorylation of protein phosphatase-1 (PP-1), an enzyme that 
dephosphorylates HSL, preventing its action[42,43]. For a visual understanding of this 
pathway, refer to Fig. 2.  
Catecholamines (Epi and NE), the greatest known stimulators of lipolysis, may 
also inhibit the pathway if it binds to the alpha-adrenergic receptor (α-AR) of the 
adipocyte. While the β-AR stimulates lipolysis, the α-AR initiates the opposite action and 
phosphorylates Protein Kinase B (PKB), a downstream target of Pi-3K[37]. The binding 
of catecholamines to one isoform of these receptors over the other is determined by the 
affinity and abundance of each receptor at the tissue level. For example, in humans, α-ARs	outnumber	β-ARs	 in	the	subcutaneous	fat	and	therefore	these	tissues	have	an	impaired	lipolytic	response[44,45].	The ratio of α-AR:β-AR is adaptable, for instance, 
the ratio is increased with a high fat diet and causes obesity in rats via hyperplasia[45,46]. 
The anti-lipolytic effects of this receptor are clear when their actions are blocked in 
adipocytes. Treatment with either isoproterenol, or epinephrine elicited a spike in 
glycerol release[47]. Treatment with yohimbine, an α-AR antagonist, elicited a similar 
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response in stimulating glycerol release, comparable to the β-AR agonist treatments, 
indicating that a blockade of these receptors enhances lipolysis [47].   
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Figure 2. The anti-lipolytic pathway Insulin acts at the insulin receptor to interact with 
insulin receptor substrate-1 (IRS-1). IRS-1 phosphorylates phosphatidylinositol-3 kinase 
(Pi3K), which activates phosphoinositide-dependent kinase-1 (PDK1). PDK1 
phosphorylates protein kinase B (PKB), which activates phosphodiesterase 3B (PDE-3B), 
which breaks down cyclic adenosine monophosphate (cAMP) to inactive 5’AMP. 
Epinephrine may stimulate the α-AR to also increase PKB phosphorylation, leading to 
enhanced PKB phosphorylation and increased activation of PDE-3B. 
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vi. Measures of Substrate Metabolism 
Determining the oxidation of substrates is beneficial in studying metabolic 
responses. In normal conditions, proteins contribute a negligible amount to energy 
metabolism, especially during exercise, and for this reason, most research focuses on the 
balance between CHO and lipid use. In animals, radio-tracers have been used to 
determine tissue utilization of various substrates[48–50] and in humans; stable isotopes 
have been used[49,51,52]. Additionally, substrate metabolism at the specific tissue level 
has been measured by examining the arterio-venous difference in substrates and their 
markers, such as glucose, glycerol or NEFAs, to determine the utilization of an individual 
tissue[53]. A major limitation of these methods is their invasiveness. For this reason, the 
respiratory exchange ratio (RER), (VCO2/VO2), is the most commonly used method to 
estimate the contribution of CHOs and lipids during a steady state (either during resting 
state, or a steady submaximal exercise)[13]. The ratio uses indirect calorimetry to 
determine substance type and oxidation rate by measuring of oxygen (O2) consumption 
and carbon dioxide (CO2) production[54].  
The basis of this relationship is that lipids and CHOs differ in their O2 production 
when being metabolized. The range for RER values is from 0.7 – 1.0, with the highest 
percentage of fat oxidation giving a value of 0.7, whereas a greatest percent of CHOs 
being oxidized is indicated by a value close to 1.0[54]. For an average resting individual 
that consumes a mixed diet, the RER would be in the range of 0.82-0.86. Substrate 
utilization at rest is determined predominantly by fuel availability. Elevated NEFAs 
enhance fatty acid oxidation while simultaneously impairing glucose utilization through 
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impairing insulin signalling[55], whereas a diet high in CHOs favours CHO 
oxidation[25,56]. 
2.2 Hormonal Influence on Energy Metabolism 
i. Overview of GC Metabolism in Normal Physiology 
Glucocorticoids (GCs) are naturally occurring hormones released from the adrenal 
cortex under the influence of the hypothalamus-pituitary-adrenal (HPA) axis[57]. Along 
with catecholamines, GCs are released as part of the fight-or-flight response during 
stress. The HPA axis is activated by the secretion of corticotropin-releasing hormone 
(CRH) from the hypothalamus which activates pituitary pro-opiomelanocortin 
(POMC)[58] gene transcription to increase adenocotropin hormone (ACTH) in the 
anterior pituitary gland. ACTH signals the adrenal glands to release GCs from the adrenal 
cortex[58]. In healthy individuals, release fluctuates throughout the day in a diurnal 
pattern, with secretion being highest upon awakening (morning) and lowest in the 
evening, although there is also a constant low concentration basal release [1]. This pattern 
is reversed in nocturnal animals (e.g. rodents). Release may also fluctuate in response to 
environmental stressors and food intake[59].  In addition to their endogenous release, 
cortisol and the various derivatives (e.g. dexamethasone, prednisolone, hydrocortisone) 
may also be consumed exogenously for their known anti-inflammatory properties to treat 
inflammation or autoimmune diseases[60].   
Once in circulation, they may exist in two forms in humans: firstly, inactive and 
bound to corticosteroid-binding protein (CBG) and otherwise, they may be active and 
circulate unbound[61]. In humans, cortisol is the active form (in rodents, corticosterone) 
and cortisone is inactive (in rodents, 11-dehydrocortcicosterone)[1]. If active, GCs may 
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readily cross the plasma membrane and may bind to the intracellular glucocorticoid 
receptor (GR)[61], a steroid nuclear receptor that is found in abundance throughout the 
body. The mineralocorticoid receptor (MR) may also be activated by GCs in some 
tissues, specifically found in the distal nephron, colon and sweat glands[34]. Activation 
of these receptors may be amplified by the pre-receptor 11 beta- hydroxysteroid 
dehydrogenase type 1 (11β-HSD-1)[34], an oxo-reductase enzyme that catalyzes the 
conversion of inactive cortisone into active cortisol[62]. 11β-HSD-1 is predominantly 
expressed in liver, adipose, bones, nervous system, muscles and lungs[63,64]. 
Conversely, GR activation may be down-regulated via the activation of 11β-HSD-2, a 
dehydrogenase pre-receptor that converts cortisol back into cortisone[65]. Through GR 
activation, GCs play a role in regulating metabolism[66], influencing growth, and 
impacting the immune system[67]. The implications of excess GCs have been extensively 
studied, although it is not entirely clear whether some of their actions are a result of direct 
genomic changes or are the indirect consequence of influencing other hormones, 
including epinephrine, insulin or glucagon. In addition to interacting with the GR, they 
are also believed to influence other hormones that may elicit a number of responses[66]. 
Hypercortisolemic models have demonstrated that elevated GCs result in insulin 
resistance, increased protein catabolism, elevated plasma glucose and lipolysis[34,60]. In 
a short-term stressed state, these responses are quite adaptive, increasing substrate 
availability for energy via the mobilization of glucose, lipids and amino acids. However, 
these responses are also seen with a chronic exposure to GCs and if sustained over a long 
period become maladaptive and are associated with insulin resistance and obesity[68]. 
For this reason, various signalling pathways tightly control GC regulation to meet the 
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demands of the body and provide feedback in order to adapt to changing 
environments[69].  
ii. GCs and fuels (CHO, Protein, Lipids) 
GCs play a role in influencing all of the major fuel sources. They are potent 
inducers of hyperglycaemia through specific actions within the various major metabolic 
tissues. They influence various counter-regulatory hormones including, insulin, 
catecholamines and glucagon, to alter fuel metabolism [70–72].  
GCs decrease insulin signalling and therefore reduce glucose uptake in the 
muscle, which is one of the most influential tissues on glucose metabolism[73–75]. In the 
liver, GCs also induce insulin resistance. This in turn results in increases in 
gluconeogenesis via the increased expression of PEPCK and G6Pase, thereby enhancing 
hepatic glucose output[72,76,77].  In the pancreas, GC overexposure results in 
impairments in insulin secretion[78,79]. Lastly, in adipose tissue, GCs reduce the 
responsiveness to insulin through decreasing IRS-1 phosphorylation and reducing PKB 
activity[80]. Studies examining the short term effects of GCs on adipose cells using 3T3-
L1 cells (30 min Dexamethasone (DEX)) have shown that GCs induce immediate effects 
on adipose by inhibiting the insulin response[81]. They do this by impairing receptor 
signalling, although they do not change receptor expression[81]. Insulin receptor 
expression is altered, however, with a long term exposure to GCs (24-hr DEX) through 
GR-mediated reductions in IRS-1 and PKB concentrations in rat adipocytes[82]. In 
tissues with decreased expression of GR and thereby reduced GC actions, there is an 
association with increased insulin sensitivity in humans[83]. 
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Figure 3.0. Metabolic effects of chronic GC exposure at the various metabolic 
tissues. HPA stimulation results in glucocorticoid (GC) release from the adrenal glands. 
Once in circulation, GCs increase blood glucose (BG) through increasing 
gluconeogenesis (GNG) in the liver via increasing GNG enzyme activity 
(Phosphoenolpyruvate carboxykinase (PEPCK) and Glucose 6-phosphatase (G6Pase), 
while impairing insulin release and insulin sensitivity at the various tissues. In adipose, 
insulin signalling is reduced through impaired insulin-receptor substrate (IRS-1) and 
protein kinase B (PKB) activity. In muscle, glucose uptake is reduced due to impaired 
insulin signalling. The pancreas has reduced beta cell function and decrases the amount 
of insulin output. GCs increase fatty acid release (lipolysis) and promote lipid storage in 
the adipose depot itself, as well as in liver (triglyceride (TG)) and muscle 
(intramyocellular lipid content (IMCL)).  
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 iii. Dual Roles of Glucocorticoids in Lipid metabolism 
 The	 actions	 of	 GCs	 on	 lipid	 metabolism	 have	 been	 extensively	 studied	through	various	models	 and	 species.	 Several	 early	 studies	used	 an	 adrenalectomy	model	 on	 rodents	 supplemented	with	 GCs	 exogenously,	 either	 to	 physiological	 or	supraphysiological	 levels.	 From	 here,	 various	 in	 vitro	 models	 using	 isolated	adipocytes	have	been	used	to	try	and	examine	specific	mechanisms.	In	vivo	murine	models,	 as	 well	 as	 human	 studies	 have	 been	 used	 to	 examine	 GC	 overexposure.	Studies	 have	 utilized	 both	 exogenous	 GC	 treatments,	 as	well	 as	 examined	 disease	states	 where	 there	 is	 a	 chronic	 elevation	 in	 GC	 release,	 such	 as	 in	 Cushing’s	syndrome.	Conversely,	the	effects	of	impaired	GCs	have	been	studied	by	examining	conditions	 with	 impaired	 GC	 release,	 such	 as	 Addison’s	 disease,	 or	 by	 using	 GR	blockers,	such	as	RU-486	[84,85].	
The lipolytic actions of GCs have been confirmed in various studies, both in vivo 
and in vitro, by increasing the rate of lipolysis through increases in lipolytic enzymes and 
receptor changes [10,86]. However, in certain circumstances, such as with very acute cell 
culture models, glucocorticoids are found to be anti-lipolytic and potentially even 
lipogenic, making their role in lipid metabolism quite perplexing[12,87]. Some of the 
differences in lipid metabolism response are related to variation between models (i.e., in 
vivo versus in vitro), concentration and duration of exposure, differences between species 
or depots, as well as some confounding effects due to the presence or absence of other 
regulatory hormones (e.g. Epi, insulin, growth hormone (GH) etc.). 	
2.3	Models	of	GC	Manipulation	and	Lipid	metabolism	
i.	Adrenalectomy	Models		
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Many	 of	 the	 early	 studies	 examining	 the	 role	 of	 glucocorticoids	 on	 lipid	metabolism	used	adrenalectomized	rodents.	The	main	benefit	of	this	model	is	that	it	eliminates	the	endogenous	release	of	both	GCs	and	epinephrine,	either	of	which	may	be	supplemented	back	with	exogenous treatment. Adrenalectomized rats had impaired 
lipolysis due to reduced β-AR concentration, as well as by reduced coupling with AC. 
This impairment was found to be corrected with short-term Dexamethasone (DEX) 
treatment (5mg/kg, 24-48hr) through increases in β-AR concentration [88]. However, 
once again some studies did not find this effect. In an adrenalectomized rat model, 
treatment with GCs did not have any enhancements in lipolysis unless treated in 
combination with  growth hormone (GH)[77]. When treated with both, the enhancement 
in lipolysis was believed to be due to an increased sensitivity to epinephrine (either by 
increased β-AR concentration or enhanced AC coupling), as measured by an increase in 
cAMP[77]. 
ii.	Cell	Culture	Models	Cell	culture	models	using	isolated	adipocytes	from	animal	or	humans,	or	3T3-L1	cells,	an	established	pre-adipocyte	cell	line	that	is	derived	from	mice,	have	been	very	useful	in	studies	examining	the	regulation	of	enzymes	with	GCs.	They	have	also	been	useful	 in	 determining	 the	 specific	 effects	 of	 GCs	 without	 the	 interaction	 of	 other	hormones[89]. Many of these models have demonstrated that GC treatment enhances 
lipolytic capacity. Isolated 3T3-L1 cells exposed to DEX for 24 hours had increased 
expression of both ATGL and HSL, key lipolytic enzymes[10,90], as well as enhanced 
PKA activity[11]. Additionally, DEX treatment (30-100 nM, 24 hours) on primary rat 
adipocytes down-regulated the expression of PDE-3B (mRNA and content), thereby 
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impairing the antilipolytic actions of insulin and further enhancing cAMP production to 
thereby promote lipolysis[11]. This was accompanied with an increase in glycerol 
release, indicating enhanced lipolysis had occurred. A study examining the cumulative 
effects of DEX (0.016ug/ml) in combination with GH (1.0 ug/mL) in isolated rat 
adipocytes, found that there was increased glycerol and fatty acid release 2 hours 
following treatment (4 hour treatment in a 2 mL volume)[91]. Interestingly, neither GH 
nor DEX alone produced a significant effect on NEFA release in isolated adipocytes, 
however, DEX did increase lipolysis in isolated rat fat pads[91]. These effects on 
lipolysis were countered when isolated adipocytes were treated with insulin in 
combination with either DEX, or DEX + GH[91]. Xu and colleagues found that 4-hour 
treatment with DEX was sufficient enough to note a slight increase in NEFA release, but 
not glycerol, a by-product of lipolysis in isolated adipocytes (10-100nM). Following 16-
24 hours, release of both glycerol and NEFAs was significantly increased in a time 
dependent manner in this model[11]. It has previously been reported that GC responses 
are not notable until approximately 4-8 hours [11,42], likely the time required to see 
responses of stimulating the GR. When treated with GR-antagonist RU-486, glycerol 
release was suppressed, further indicating that these were genomic, receptor mediated 
adaptations[11].  
There is reason to believe that GCs exhibit very different immediate, non-genomic 
immediate actions. Interestingly, 3T3-L1 cells acutely exposed to corticosterone (1 hour), 
have a decreased rate of glycerol release compared to controls[12]. At this exposure time, 
increasing the concentration of corticosterone resulted in further decreases in glycerol 
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release, indicating anti-lipolytic actions in an acute setting[10]. Further investigation of 
these potential non-genomic actions is required in an in vivo model. 
iii.	Human	and	In	Vivo	Rodent	Models	
Alterations in GC concentrations in vivo have been extensively studied in both in 
vivo animal models and in humans, but similarly to cell culture studies, most research has 
focused on the chronic adaptations. In vivo models have been beneficial for examining 
the interaction between GCs and various regulatory hormones, most notably, insulin.  
In rodents, implantation of a corticosterone pellet (300 mg) resulted in an increase 
in lipolysis when measured after 10 days, despite an increase in visceral adiposity[10]. 
Studies examining short-term GC over-exposure (~6 hours) in humans also elicited a 
lipolytic response[92]. Healthy men that received an infusion of hydrocortisone had 
increased glycerol in the interstitial and femoral adipose tissue, as well as systemic 
glycerol when measured up to 6 hours after infusion[92], comparable to the expected 
time of genomic effects to occur in cell culture models. Interestingly, in a study using 
healthy subjects that had hydrocortisone infused to achieve plasma cortisol 
concentrations of 1500–1700nmol/L, it was observed that  4-5 hours following treatment 
there was an increase in lipolysis in the subcutaneous adipose tissue of the limbs. 
However, in the abdominal subcutaneous adipose, there was a decrease in NEFA release 
and HSL activity, suggesting a potential anti-lipolytic mechanism in this depot [93]. This 
study provided insight to the potential depot specific differences in GC responses, as 
observed in the phenotype of individuals with chronic hypercortisolemia (i.e.; Cushing’s 
syndrome (CS)). This condition results in increased abdominal adiposity, while muscle 
and adipose is wasted in the limbs. Studies on CS patients have demonstrated that they 
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have reduced lipolytic activity, as indicated by impaired NEFA turnover[94,95]. 
Additionally, obese individuals have local elevations in GC activity through increased 
GR and 11β-HSD-1 content in adipose tissue, indicating that GCs are involved in 
promoting adipose storage[96].  
As mentioned earlier, although some short-term exposure studies (6-48 hours) 
have been performed, the immediate, non-genomic actions have not been as extensively 
studied in an acute in vivo model. In rodents, a handling-stress model has been used as an 
effective way to induce a stress response and it has been found that 165 minutes 
following stress results in an efflux in NEFA release[97]. However, these studies are 
limited because it is difficult to determine if these changes are the result of GC 
elevations, or the more immediate actions of Epi and NE that are also released in a stress 
response. Additional investigation is required to further understand the immediate actions 
of GC.  
2.4 GCs in the Subcutaneous versus Omental/Visceral Depots 
Excessive accumulation of body fat is known to increase the risks of metabolic 
abnormalities and the distribution and type of fat are also important factors that 
contribute to potential complications. Excessive android adiposity (abdominal 
accumulation), in combination with increased visceral fat poses an increased risk for 
associated metabolic complications, such as hyperglycaemia, insulin resistance and 
elevated triglycerides[93,94]. Individuals with a gynoid distribution (increased lipid 
accumulation in gluteo-femoral region) have a larger proportion of subcutaneous fat and 
increased accumulation of this type of fat is not associated with metabolic aberrations.  
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As discussed, the phenotype of individuals with hypercortisolemia is unusual. GCs 
induce adiposity through stimulating adipogenesis, as well as enhancing adipocyte 
hypertrophy[100]. Microarray studies have determined that GCs have a powerful effect 
on influencing gene networks that regulate human adipose tissue, promoting lipid 
accumulation in abdominal adipose tissue (both omental and subcutaneous)[101]. 
Looking at the phenotype of these individuals with chronically elevated GCs, it is clear 
there is some altered regulation of adipose tissue and that different adipose depots elicit 
difference responses. Increases in omental (i.e. visceral) adipose tissue are associated 
with elevated cortisol, androgens and reduced GH [102]. As stated, subcutaneous adipose 
of the extremities is diminished in these individuals. Various studies have examined the 
potential mechanisms for these differences [8,96,101–103]. Considering that in 
conditions such as metabolic syndrome or obesity, systemic GC levels may remain in the 
normal range, one of the major hypotheses is that the specific depots are susceptible to 
tissue-specific enhanced activation of GCs through increased GR or 11β-HSD-1 
expressions [104,105]. 
11β -HSD1 content has been established as an important predictor of adiposity[103]. 
Higher levels of 11β-HSD-1 and cortisol content have been found in omental compared 
to subcutaneous adipose tissue in women with excess abdominal adiposity[96]. Both 
omental and subcutaneous adipose tissue were extracted from healthy individuals and 
exposed to elevated DEX (20 nmol/l in 1mL) and insulin, which was chosen to replicate a 
stress response. 11β-HSD-1 mRNA content and activity was enhanced in the omental 
adipose tissue, indicating a role in which GCs contribute to visceral obesity[106]. This 
visceral-specific up-regulation of 11β-HSD-1 activity is also seen in Zucker rats, a 
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diabetic rodent model[107]. In the visceral versus subcutaneous adipose of obese 
patients, there is increased 11β-HSD-1 and cortisol content[103]. Additionally, this depot 
had an increased expression of enzymes involved in fatty acid metabolism when 
compared to the subcutaneous depot in both obese and healthy subjects[103]. Increased 
local activation of GCs is accompanied by increased GR density in omental compared to 
subcutaneous human adipose tissue and more GC binding occurs in intra-abdominal 
adipose[83,108]. When examining RNA sequencing on abdominal subcutaneous adipose 
from patients with Cushing’s disease, it was found that GCs also play a role in up-
regulating lipogenic genes[109].  
Adipocytes treated with DEX have an enhanced capacity to uptake free fatty acids via 
DEX-induced increases in LPL activity, a known lipogenic protein. The increase in LPL 
activity more pronounced in omental compared to subcutaneous adipocytes, further 
contributing to a potential mechanism for GCs to promote central adipocyte 
hypertrophy[110].  
Contrary to the impaired insulin sensitivity that GC administration causes in visceral 
adipose tissue and muscle, short-term GC administration (14 hour hydrocortisone 
infusion of 0.2mg/kg*hr) enhances insulin sensitivity in subcutaneous adipose tissue[8]. 
This is also seen in subcutaneous adipocytes treated with DEX[111]. Considering that 
GCs induce insulin resistance, it is plausible that the enhanced lipolytic activity in this 
depot may be an indirect effect of GCs through impairing insulin signalling. 
2.5 GC Association with Dysregulation and Metabolic Disease 
Despite the benefits being a potent anti-inflammatory agent, chronic overexposure 
of GCs results in CS—a clinical condition associated with metabolic complications, 
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including central adiposity, muscle wasting, insulin resistance, hepatic steatosis, and 
dyslipidemia. The most common etiologies of CS are pituitary adenomas (most 
frequently), which increase the endogenous production of ACTH, but adrenal hyperplasia 
or adrenocortical tumours also account for many cases [112,113]. The excess production 
impairs the feedback to the HPA axis. Additionally, CS may result from excess exposure 
to exogenous corticosteroids or synthetic GCs, usually from oral administration, but also, 
less frequently, may occur from topical exposure[114].  
Metabolic syndrome (MetS) is a multifactorial condition characterized by a 
cluster of risk factors including, increased waist circumference, hyperglycaemia, 
dyslipidemia, hypertension and obesity[115–117]. Many phenotypical and symptomatic 
similarities have been observed between MetS and CS, leading many to hypothesize that 
cortisol may be involved in the pathophysiology of MetS[68,118]. The physical 
Cushingoid features are distinct, with excessive android obesity and very thin extremities. 
While the wasting at the extremities is a feature that is unique to Cushing’s, the excessive 
abdominal obesity is similar to that of a MetS patient. In the liver, patients with adrenal 
cortical incidentalomas and CS have reduced HDL and cholesterol levels accompanied 
with elevated triglycerides, resulting in dyslipidemia[119]. Additionally, elevated cortisol 
is consistently associated with insulin resistance [120]. It has also been found that type 2 
diabetes is associated with variations in 11β-HSD-1 gene expression, indicating increased 
local activation of GCs in the tissues[121]. 
In addition to the metabolic consequences, there is also an association between 
psychological symptoms of depression and anxiety, and central obesity, insulin resistance 
and cardiovascular morbidities[120,122]. In obese children, symptoms of anxiety and 
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depression correlate with elevated salivary cortisol levels throughout the day[123]. In 
men, cortisol metabolites were increased with depression and central obesity[124]. 
The reduced muscle mass in CS patients impairs their exercise capacity and even 
if exercise is performed, there is an impaired ability to lose weight. Fortunately, the 
negative metabolic effects of this condition are countered when treated with RU-486, a 
GR antagonist. It was found that with RU-486, CS patients have significant 
improvements in metabolic outcomes, such as decreased HbA1c and reduced waist 
circumference[125]. 
2.6 Lifestyle Influences on metabolism 
Although there are genetic components that contribute to metabolism, environmental 
factors significantly influence metabolic health and regulation. There are a number of 
environmental factors that influence this relationship; including, sleep patterns (altered 
circadian rhythm), temperature, diet and activity.  Metabolic homeostasis is achieved 
through a balance of energy input being met with fuel utilization, so for this reason two 
of the most influential factors of energy balance are diet (energy input) and physical 
activity (energy output).  
i. Diet 
In addition to the basic input versus output requirements, macronutrient intake 
must also balance oxidation[25]; for this reason, dietary choices, in addition to the overall 
calories, have a significant impact on energy metabolism. Unbalanced diets with 
significant elevations of a particular macronutrient leads to metabolic aberrations and 
dysregulation[126]. For example, high fat diets (HFDs) significantly increase adiposity 
and are a main factor in inducing the development of type 2 diabetes, as seen in various 
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human and rodent studies[127–129]. Increases in adipose accumulation not only affects 
adipose metabolism, but also impacts how the body processes other substrates. HFDs 
impair insulin sensitivity via impairing GLUT4 mRNA and protein content in adipocytes, 
leading to less glucose uptake and oxidation[130].   
Additionally, diets relying predominantly on protein may provide insufficient levels 
of CHOs, and protein must be converted to glucose in a process termed protein sparing 
[131,132]. Eating a balanced diet rich in nutrients is recommended to maintain a healthy 
metabolism.  
ii. Exercise 
Exercise has a major influence on energy substrate metabolism. Changes occur 
during exercise, but the body also adapts to influence metabolism following the 
completion of the activity. During exercise, there is an increased metabolic demand for 
energy to sustain muscle activity, which places the body in a state of energy deficit and 
stress.  
Depending on the type and duration of the activity, the body adjusts its fuel 
utilization to meet the workload demand. Various studies have examined how fuel 
selection is manipulated by exercise type and intensity though assessing changes in RER 
[54,133]. At the onset of a moderate intensity (40-60% VO2Max) endurance exercise, an 
immediate rise can be seen in RER, but as the exercise continues and exceeds 
approximately 30 minutes, RER decreases, indicating an increase in the reliance on lipid 
oxidation[54]. While high intensity exercise favours CHO oxidation from blood glucose 
and muscle glycogen stores, as CHOs yield the most energy (in the form of adenosine 
triphosphate) per each molecule that is oxidized, the optimal type of exercise to utilize 
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lipids as the predominant fuel is low-intensity endurance exercise, below 50% of 
VO2Max[49]. In addition to the type of exercise, other factors influence fuel selection 
with physical activity. For instance, trained athletes have a shift in RER to utilize lipids 
more readily than non-trained individuals, even at rest [134].  
iii. Aerobic Exercise and Hormonal Regulation 
It is well known that exercise has numerous benefits in improving metabolism, 
reducing adiposity and increasing muscle mass. These changes are the result of 
physiological adaptations that occur with activity. Acutely, a bout of exercise is a stressor 
to the body. Activating the stress response as an adaptable response in order to maintain 
homeostasis and meet the increased metabolic demand. The stress response triggers the 
immediate activation of the Autonomic Nervous System (ANS) in what is known as the 
“fight-or flight” response[135] and a signal is sent down the spinal cord to trigger the 
release of NE and adrenal glands to release a flux of Epi. The hypothalamus also induces 
the cascade of signals to also promote the release of GCs from the adrenals[135]. 
Although there are two major types of exercise, resistance and continuous (aerobic) or a 
combination of the two, this review will only be focusing on the physiological response 
for continuous/aerobic forms of exercise.  
Both catecholamines and GCs influence metabolism directly, as well as by 
altering the regulation of other neuroendocrine hormones. Epinephrine, a major 
catecholamine, has been shown to trigger glycogenolysis in muscle to allow glucose to be 
used as a fuel[136]. While epinephrine inhibits insulin, it enhances the ability of the 
muscle to take up plasma glucose through contraction mediated glucose uptake, (insulin-
independent)[137]. Following an exercise bout, however, there is also an enhanced 
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sensitivity to insulin that lasts up to 48 hours. This further mediates glucose uptake 
(insulin-dependent) [138–141]. In addition to these effects, interleukin-6 (IL-6) is 
increased during exercise from working muscles, partly under the influence of 
epinephrine. IL-6 is involved in increasing GLUT4 protein content in white adipose 
tissue following exercise to enhance glucose uptake[142].  
Epinephrine is the major hormone involved in initiating the mobilization of free 
fatty acids to be available to be used as a fuel. During exercise, epinephrine acts on the β-
AR to trigger the lipolytic pathway to release NEFAs to the plasma where working 
muscles are then able to use them as fuel to be oxidized[44]. Contrary to their lipolytic 
role, epinephrine is also the preferred amine to the α2-AR, which promotes anti-lipolytic 
actions[143]. Additionally, IL-6 indirectly increases lipolysis in glycolytic muscles and 
various studies have demonstrated that a single bout of continuous exercise reduces 
intramyocellular lipid content (IMCL) [144].  
iv. Role of GCs in Aerobic Exercise 
In a state of exercise, GCs have typically been shown to be quite beneficial in 
improving exercise performance and assisting in maintaining homeostatic regulation. 
During exercise, it has been found that rats that received corticosterone took significantly 
longer to reach exhaustion than those that did not, demonstrating that the corticosterone 
enhanced the endurance capacity of the rats by increasing the amount of time it took to 
reach exhaustion[145].  
Exercise induces a rise in GCs most significantly when working at high 
intensities[146]; however, in a resting state, chronically trained individuals have reduced 
GC levels[147,148]. In addition to the amount of GCs in circulation increasing during 
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exercise, tissues also increase their sensitivity to GCs [149]. In muscles, this may be done 
to help reduce the inflammatory reaction caused during exercise by reducing cytokine 
synthesis, thereby limiting the amount of damage at the muscle during exercise[149]. 
Twenty-four hours following exercise, tissue sensitivity to GCs has been shown to 
decrease[149–151], which may help in preventing excessive catabolism to muscle that 
may otherwise be observed with an overload of GCs.  
In terms of their role in metabolism with exercise, GCs cause a rise in circulating 
glucose by increasing glycogenolysis at the liver, while reducing the muscular sensitivity 
to glucose[152]. These adaptations may be used as a mechanism to prevent 
hypoglycaemia with exercise from occurring. The presumed role of GCs in lipid 
metabolism, as cited in various textbooks, is that they are lipolytic to allow NEFAs to be 
used as a fuel[152,153]. Considering their role in impairing insulin signalling, however, 
this has not actually been studied in vivo during exercise and further research is required 
to determine if they have alternative acute actions. 
2.7 Clinical Relevance/Gaps in the literature  
GCs have been prescribed for many years as a potent anti-inflammatory agent, 
both for acute injuries as well as chronic conditions, such as rheumatoid arthritis and 
some forms of cancer. Considering the detrimental effects of chronic hypercortisolism, 
examining the immediate effects further would be useful in helping to understand their 
specific actions and implications on metabolism. The most curious uncertainty about GCs 
is the perplexing role they play on lipid metabolism and further investigation is required 
to better understand their function. Acutely, they are believed to enhance systemic 
lipolysis as well as NEFA uptake, although this may be due to the associated rise in 
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catecholamines with a stress response. The need to examine the interaction of GCs and 
exercise is also intriguing.  GCs fluctuate during exercise and influence various other 
hormones, leading to serious alterations in metabolism. This information would be of 
interest to many athletes that use GCs for injuries, providing insight on their potential 
influence on athletic performance. 
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3.0 RATIONALE AND OBJECTIVES  
3.1 Background and Rationale 
Glucocorticoids are naturally occurring steroid hormones that rise in 
concentration during situations of stress, starvation and exercise. GCs promote insulin 
resistance and induce epinephrine release from the adrenal medulla[154]. They play a 
perplexing role in lipid metabolism and may exert pleotropic effects. They are typically 
stated to be “lipolytic” by most physiological textbooks [153] but the mechanism of 
action for this effect is somewhat unknown. Elevations in GCs have been shown to be 
associated with epinephrine and norepinephrine secretion and lower insulin sensitivity, 
both of which may help facilitate lipolysis [38,155]. Previous research from our lab 
supports the lipolytic actions of GCs, but only when GCs are elevated long enough to 
increase the gene transcription of ATGL and/or HSL[10]. It is also apparent in 3T3-L1 
cell culture models that GCs induce acute antilipolytic actions, particularly at higher 
dosages of exposure[12].  This latter point supports the clinical observation that 
hypercortisolemia is strongly associated with central obesity [156]. Although several 
studies have examined the chronic effects of glucocorticoids on body adiposity and 
insulin sensitivity[60,62,81], less is known about their immediate action on adipose tissue 
metabolism. For this reason, we designed a rodent exercise model to examine the acute 
role of glucocorticoids in relation to lipid metabolism once activated by a stress response, 
in this case, exercise. The model will assess molecular and in vivo markers of adipose 
tissue lipolysis as well as catecholamine and insulin levels following acute GC treatment 
and hopefully gain insight as to which mechanism plays a more dominant role in lipid 
regulation.  
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3.2 Purpose 
The purpose of this study is to gain insight into the role of glucocorticoids in lipid 
metabolism and to determine if an acute dose will induce a lipolytic response once 
activated by exercise. Additionally, this study will examine the extent to which 
glucocorticoids influence insulin concentration and the phosphorylation of lipolytic 
enzymes, as well as determining if these relationships are influenced by exercise. The 
acute effects of glucocorticoids have previously been examined in our lab in vitro, this 
model will assess the role in an in vivo setting. 
3.3 Hypothesis 
We hypothesize that acutely elevated levels of GCs (corticosterone) will attenuate 
the lipolytic responses seen at rest and with moderate exercise.  
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4.0 MANUSCRIPT  
THE ACUTE ROLE OF GLUCOCORTICOIDS DURING EXERCISE ON LIPID 
METABOLISM1	INTRODUCTION 
Glucocorticoids (GCs) are hormones that are released from the adrenal medulla at 
low levels throughout the day and their concentration significantly increases with a stress 
response[154]. However, in cases with increased stimulation of the adrenal response, 
circulating levels of GCs are elevated and they disrupt metabolic homeostasis. Despite 
their known benefits as potent anti-inflammatory agents, they have been proven to cause 
detrimental effects when chronically elevated, resulting in obesity, hyperglycaemia and 
insulin resistance. This has been observed in various rodent models in which 
glucocorticoids are increased exogenously, or in human studies of hypercortisolemia, 
where GCs were either given as treatment, or were naturally elevated, such as in the 
medical condition, Cushing’s syndrome.  
With regard to lipid metabolism, GCs are typically stated to be “lipolytic” in most 
physiological textbooks [153], in that they are believed to increase the flux of substrates, 
yet the mechanism of action for this supposed effect is unknown. Elevations in GCs have 
been shown to be associated with increased catecholamine secretion and reduced insulin 
sensitivity, which are potential mechanisms in which they may facilitate lipolysis 
[38,155]. Cell culture studies using 3T3-L1 cells support the lipolytic actions of GCs, but 																																																								1	Aoibhe Pasieka1, Emily Dunford1, Deanna Porras1, Michael Riddell1 
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this is only the case when elevated long enough to increase the gene transcription of 
ATGL and/or HSL[157]. It is, however, also apparent in these models that GCs induce 
acute antilipolytic actions, particularly at higher dosages of exposure[12].  This latter 
finding is more supportive of the clinical manifestations of chronic hypercortisolemia and 
its association with central obesity[156]. Several studies have demonstrated that 
chronically elevated glucocorticoids have profound effects on increasing body adiposity 
while impairing insulin sensitivity[158], However, their immediate actions on lipid 
metabolism have not been specifically demonstrated in vivo. For this reason, we designed 
a rodent exercise model to examine the acute role of glucocorticoids in relation to lipid 
metabolism once activated by a stress response—in this case, exercise. The model was 
designed to assess molecular and in vivo markers of adipose tissue lipolysis, as well as 
glycemic markers following acute GC treatment with the objective of hopefully gaining a 
better understanding of lipid regulation with exercise.  
METHODS 
Ethics Statement 
The following study was been approved by the York University Animal Care 
Committee (Protocol # 2015-3) and was carried out in accordance with the regulations of 
the Canadian Council for Animal Care guidelines.  
Experimental Design 
Sixty male Wistar rats (Charles River Laboratory, approximately 225-250 grams 
upon arrival) were used in this study. Rats were acclimated to the York University vivaria 
for one week after arrival and were housed in a humidity and temperature controlled 
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room in a 12 hour : 12 hour light-dark cycle. All animals had access to a standard chow 
ad libitum diet. Following the one-week acclimation, rats were individually housed and 
randomly assigned to one of 4 treatment groups. A schematic of this protocol is 
represented in Fig. 1.1. Animals were either assigned to an exercising or sedentary 
protocol, and from here they were further separated to receive either Vehicle (25% 
DMSO in saline), or Corticosterone (25 mg/kg body weight in 25% DMSO in saline). All 
groups were acclimated to running treadmills for 3 days within a one-week period. 
Intensity and duration were increased in each acclimation session. On the first day of 
acclimation, rats ran for 10 minutes at a pace of 10 meters/minute with 0% incline. On 
the second day, the speed was increased to 20 meters/minute with a 0% incline for 10 
minutes. On the final acclimation day, they ran for 20 minutes at 20 meters/minute with 
0% incline.  
After the one-week acclimation, the experimental protocol commenced (Fig. 1.2). 
Approximately 4 animals underwent the experimental protocol each day with two 
overlapping at a time. Experiments were performed in the morning when basal 
corticosterone levels were lowest. For this protocol, each animal received a saphenous 
blood draw, which was collected as a pre-treatment measure (t = -25min) and at this time, 
blood glucose was also measured. Approximately 15 minutes following this, animals 
received an intraperitoneal (i.p.) injection of their treatment (t = -15 min), either the 
vehicle solution, or corticosterone. Immediately following the injection, animals were 
placed in Comprehensive Lab Animal Monitoring System (CLAMS) treadmills, which 
allowed the measurement of  the respiratory exchange ratio (RER) for each animal. A 
period of 15 minutes elapsed before turning on the treadmills in order to establish a stable 
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basal reading of ventilation and RER. Once this equilibration period was complete (t = 0 
min), the treadmills were turned on for the exercise groups to 20m/min, 0% incline, and 
remained on for 45 minutes. The sedentary animals remained in the CLAMS treadmills 
for this 45-minute period, but the running belt was turned off. For both groups, RER was 
measured throughout.  
Immediately after the 45-minute exercise (or 45 minute sedentary period), 
animals were removed from the treadmills and each received a tail prick in order to 
measure post-treatment blood glucose. Directly following this, animals were placed in an 
induction box filled with isoflourane and oxygen, which was used as an anaesthetic. Once 
fully unconscious, animals were euthanized and the renal vein was cut to allow for the 
collection of a post-treatment blood sample. Additionally, a fragment of the liver was 
dissected for additional blood collection from the trunk. Concurrently, tissues (peritoneal 
adipose depots) were collected and immediately placed in microtubes and put into liquid 
nitrogen. Tissues and plasma samples were then transferred to storage at -80oC to be 
preserved for future assays. 
Drug Preparation 
Our vehicle was prepared as a stock solution of 25% dimethyl sulfoxide (DMSO) 
in saline. Corticosterone (Sigma-Aldrich, Cat # C2505) was also prepared in a stock 
solution, where the corticosterone was dissolved into the vehicle (0.005 mg/ml) and 
sonicated immediately before use. Each animal in this group received 25mg/kg body 
weight, which was considered to be a moderately high yet safe dose that had been 
previously published in other studies [159,160].  
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Plasma Analyses 
Plasma was collected in potassium-coated EDTA microvette capillary tubes 
(Sarstedt, Cat #16.444.100). Blood was collected from the saphenous vein for the pre-
treatment blood draw and during euthanization from the renal vein for the post-treatment 
measures. Immediately after collection, 10µL of Trasylol was added as a proteinase 
inhibitor before samples were placed on ice. Samples were then centrifuged for 5 minutes 
at 15,000 rpm before plasma was pipetted out into polyethylene tubes. Samples were 
placed back on ice before being transferred to -80oC storage where it remained until used 
for later analysis. Plasma was used for various analyses including non-esterified fatty 
acid, glucagon and insulin concentrations, which were assessed using enzyme-linked 
immunosorbent assays (ELISAs) (Wako, Cat #999-34691; Mercodia, Cat #10-1281-01; 
Crystal Chem, Cat #90060) and corticosterone concentration was assessed using a 
radioimmunoassay (RIA) (MP Biomedicals, cat#07-120103).  
Western Blotting 
Radioimmunoprecipitation assay (RIPA) buffer (150mM NaCL, NP-40, sodium 
deoxycholate, SDS, 50mM Tris base) was supplemented with protease inhibitor cocktail 
(Sigma-Aldrich, Cat #P8340) and phosphatase inhibitor cocktail (Sigma-Aldrich, Cat 
#P0044). The solution was added to adipose tissue samples (approximately 50mg) at a 
concentration of 10mL/mg. Samples were homogenized using a D2400 Homogenizer 
(Diamed) for 6 cycles of 45 seconds. Samples were then placed on ice for 10 minutes and 
then centrifuged at -4oC for 10 minutes at 14,000 rpm. Supernatant was pipetted out and 
transferred to microtubes. Protein concentrations were determined using a commercially 
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available bicinchoninic acid assay (BCA) and samples were stored at -80oC until later 
use.  
Thirty micrograms of protein from the various fat depots was run on a 10% SDS-
page gel before being transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-
Rad, Canada). Membranes were then blocked for 1 hour at room temperature in 5% skim 
milk dissolved in Tris-buffered saline with Tween 20 (TBST). Next, membranes were left 
to incubate in their primary antibody at a concentration of 1/1000 (pHSL, tHSL, 
Perilipin-A, PKA-substrate indicator) or 1/10,000 (beta-actin) overnight at 4oC. The next 
morning, the primary antibody was removed and membranes were washed in TBST for 3 
cycles of 10 minutes. Membranes were then incubated in their secondary antibody for 1 
hour at room temperature. The secondary antibodies used were goat-anti-mouse when 
beta-actin was the primary antibody (1:10,000, ab6789, Abcam, Cat #ab6789), or goat-
anti-rabbit for all other primary antibodies (1:10,000, Abcam Cat #ab6721). Secondary 
antibodies were diluted into in the 5% skim milk in TBST. Membranes were again 
washed in TBST for 3 cycles of ten minutes. All membranes were images using a Kodak 
In vivo FX Pro imager, with Carestream used as the molecular imaging software.  
 
Statistical Analyses 
 
All data was represented as mean ± standard deviation. Two-way ANOVA 
analyses were used to compare differences between groups and a cut off of p<0.05 was 
considered to be significant. For significant values, Tukey’s post-hoc test was used to 
determine differences between specific groups (treatments and activity).  
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Figure 1.1 – Animal treatment groups. Animals were randomly divided into one of 4 
groups. The first two groups were sedentary and received either vehicle (SV) (25% 
DMSO in saline) or corticosterone (SC) (25 mg/kg). The other animals were exercisers 
and were also subdivided to receive either vehicle (EV) (25% DMSO in saline) or 
corticosterone (EC) (25 mg/kg). 
 
Figure 1.2 – Acclimation protocol to treadmills. All animals (exercise and sedentary 
groups) were acclimated to the treadmills in the week leading up to the day of 
experiments in order for them to be able to adequately perform the exercise on the day of 
experiment. On day 1, animals exercised at a pace of 10 m/min for 10 minutes. They had 
a rest day and on day 3 were acclimated again, but the speed was increased to 20 m/min. 
This exercise lasted for 20 minutes. Animals had an additional rest day before performing 
their final acclimation training on day 5, where they exercised at 20 m/min for 30 
minutes. 
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Figure 1.3 – Experimental protocol. Animals underwent a saphenous blood draw at t = 
-25 min. At t = -15 min, animals received an i.p. injection of their treatment. Animals 
were immediately placed inside the metabolic treadmills. At t = 0 min, after a basal RER 
value was established, exercise commenced for EV and EC groups. At this time, SV and 
SC animals remained on the inactive treadmills with them turned off. At t = +45 min, 
animals were euthanized and tissues and post-treatment blood samples were collected. 
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RESULTS 
 
Plasma corticosterone is significantly increased one hour following corticosterone 
injection. (Fig. 2) In order to test our model and ensure that our corticosterone was 
sufficiently increased in our groups, a RIA kit was used to measure plasma corticosterone 
concentrations. Plasma corticosterone concentration was elevated in the groups that 
received an i.p. injection of corticosterone compared to vehicle controls. There was a 
main effect of corticosterone treatment to increase plasma corticosterone levels 
(p<0.0001), as well as an interaction between corticosterone treatment and activity 
(p<0.0001). Corticosterone trended towards being significantly greater than vehicle in a 
sedentary state (350.48 ± 63.56 ng/mL, to 600.01 ± 43.59 ng/mL, p = 0.052) and when 
exercising EC was significantly greater than the EV control (376.54 ± 43.51 ng/mL , 
748.01 ± 115.63 ng/mL , p = 0.0005).  
Corticosterone fluctuates in RER at rest, but does not have an effect with exercise. 
(Fig. 3) In the sedentary groups, there was a significant interaction between time and 
treatment (p = 0.0033) in RER values, but no main effect of treatment or time. While the 
sedentary group did not fluctuate much throughout the duration of the experiment, the 
corticosterone group had an initial rise in RER up until t = +10 min, before it proceeded 
to decline, indicating a shift towards favouring lipid oxidation, which continued until the 
end of the experiment (t = +45 min). There was no significant interaction between 
treatment and time in the exercising groups; however, there was a significant effect of 
time (p<0.0001). Both vehicle and corticosterone-treated animals had a comparable rise 
in RER after exercise commenced, then gradually declined for the remainder of the 
exercise.  
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Non-esterified fatty acid concentration is not significantly altered after 1 hour of 
corticosterone treatment. (Fig. 4) As a primary measure of lipolysis, an ELISA kit was 
used to measure NEFA concentration before animals received treatment (t = -25 
minutes), as measured from the saphenous vein, as well as at t = +45 minutes, with blood 
collected from the trunk during euthanization. Pre-treatment values were used to express 
a range of normal NEFA concentrations for healthy controls. There were no differences 
in NEFA concentrations between sedentary and exercising groups, additionally, there was 
no significant effect of corticosterone treatment.  
Peritoneal lipolytic enzyme activity in corticosterone treated animals is affected by 
activity. (Fig. 5) Western blot analyses were performed on the peritoneal fat depot to 
determine the activity of the major lipolytic enzymes in the fat pad. All measurements 
were analyzed using tissues collected one hour following corticosterone treatment (t = 
+45 minutes). Phosphorylated HSL was made relative to total HSL in order to get a 
measure of its activity and a phosphorylated PKA substrate-indicating antibody was 
made relative to total perilipin in order to assess perilipin activity. All samples are 
represented as a fold change from the control (SV) on the gel they were run on. Both 
HSL and perilipin activity were not significantly different from the sedentary control 
(SV). However, perilipin activity in the SC was significantly increased compared to the 
EC group (p = 0.0469).  
Blood glucose is not altered with 1 hour of corticosterone treatment, but rises with a 
45-minute exercise. In order to determine if corticosterone significantly alters blood 
glucose, blood was collected from the saphenous vein prior to injection at t = -25 minutes 
(pre-treatment values were used to express a range of normal glycemic concentrations for 
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healthy controls, indicated as grey shaded area, Fig. 6.1). Additionally, blood glucose was 
measured by a tail prick at t = +45 minutes. Corticosterone did not alter blood glucose 
relative to vehicle one hour following injection. It did, however, significantly rise with 
exercise for both treatment groups (SV; 6.82 ± 0.70, SC; 6.08 ± 0.69, EV; 10.3 ± 1.57, 
EC; 10.8 ± 1.27, p < 0.0001).  
Plasma insulin concentration is not significantly altered with corticosterone treatment 
or 45 minutes of exercise. (Fig. 6.2) GCs are consistently associated with the 
development of insulin resistance with chronic exposure, but their immediate interactions 
have not yet been examined. No significant different occurred between any of the groups. 
All insulin values were measured using plasma from trunk blood (t = +45 minutes). Pre-
treatment values were used to express a range of normal insulin concentrations for 
healthy controls, as indicated by the grey shaded area.   
Plasma glucagon increases with corticosterone treatment at rest, but no difference in 
exercising animals. (Fig. 6.3) The rapid effects of glucocorticoids on glucagon are 
unknown, so to examine this an ELISA kit was used to assess plasma glucagon 
measurements. There was a main effect of treatment (p = 0.0032), but not activity. In a 
sedentary state, plasma glucagon in corticosterone treated animals was approximately 3-
fold higher than sedentary controls (SV; 20.23 ± 3.81, SC; 53.45 ± 8.65 pmol/L, p 
<0.0226). There were no detectable changes between the corticosterone versus vehicle 
treatment in exercising animals.  
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DISCUSSION  
Glucocorticoids are consistently considered to be lipolytic due to their ability to 
increase the expression of lipolytic enzymes. Acute models of hypercortisolemia have 
shown that GCs induce lipolysis in isolated adipocytes, in rodents and in humans, yet 
taken together with the increased adiposity that occurs with hypercortisolemia or CS 
patients, makes the picture less clear. Additionally, it has also been found that CS patients 
have reduced NEFA turnover compared to controls[94]. Also, while some studies have 
found conflicting data, these were not found to be significant[95]. Currently, in vivo 
studies examining the rapid, non-genomic effects of GCs are lacking in vivo. Recent 
work in cell culture models indicate that it is possible that GCs initially induce anti-
lipolytic effects after as little as 30 minutes to one hour, as indicated by a reduction in 
glycerol release with corticosterone treated 3T3-L1 cells[12]. In another model, DEX 
treatment did not increase free fatty acid release in isolated adipocytes, while it did when 
examining the entire fat pad[91]. For this reason, we designed our model to determine if 
the same response would be seen in vivo. Our treatment successfully altered the amount 
of circulating corticosterone between groups (Fig. 2). When comparing our sedentary 
groups, there was more fluctuation with corticosterone treatment in RER response. GC 
treated animals had an initial rise in RER up until t = +10 min, before shifting towards a 
decrease in RER until the end of the experiment (Fig. 3A). This shift towards a decrease 
in RER indicates a favouring of lipid oxidation over CHO utilization[56]. This drop in 
RER did not reach significance when compared to the SV, but it would be beneficial to 
examine determine if this group would reach significance after increasing the number of 
subjects. When examining NEFA concentrations, however, there was no change 1 hour 
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following corticosterone injection (Fig. 4). Considering that this was a static 
measurement of assessing NEFA content, it is possible that the flux of NEFAs is altered 
with corticosterone, but is perhaps matched by increases in oxidation, maintaining the 
plasma NEFA content comparable to controls. Despite this, there was an increase in 
perilipin (but not HSL) activity in the SC compared to the EC group, appearing to have 
an increased phosphorylation in the peritonenal adipose tissue. It is important to note, 
however, that this trend did not reach significance when compared to the SV group. 
Previously, it has been reported that it requires 4-6 hours before seeing the effects of 
GCs, due to the delay required to see any receptor mediated genomic changes[11,42]. 
However, this trend would suggest a possible immediate non-genomic response to 
increased lipolysis by enhancing lipolytic enzyme phosphorylation. It is still unclear, 
however, if these changes were a direct response to increased GCs, or if they were an 
indirect effect of other hormones that may have altered regulation by GCs. 
Catecholamines, for example, is often associated with a rise in GCs as they are both 
released as part of the stress response [3]. Epinephrine and norepinephrine are known to 
have more immediate effects than GCs. Exercise studies comparing healthy controls to 
paraplegic individuals (impaired SNS activity) have demonstrated that catecholamine 
release may be the driving inducer of a lipolytic response with exercise[161]. This may 
not give the full picture though; treatment with propranerol, a β-AR blocker, only 
partially inhibits lipolysis during exercise[162]. Further investigation into the specific 
mechanisms involved in this increase in lipolytic action during exercise is still required.  
As exercise is marked by a sharp increase in metabolic demand, it places the body 
in a state of stress. A rise in fuel mobilization occurs in order to meet these demands. For 
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decades, it has generally been accepted that GCs induce a rise in FFAs during 
exercise[13,152], however, no study has objectively measured this and any increases in 
NEFAs or glucose may be due to the immediate actions of catecholamines with exercise. 
Our data indicates that there is no reason to believe that corticosterone is lipolytic in an 
acute state of exercise. No differences in RER were observed when comparing EV to EC 
during exercise (Fig. 3B). A trend towards an initially reduced RER with corticosterone 
treatment was observed. After further examination of all baseline RER points (Fig. S3.0), 
it was determined that there was an effect of both treatment and time, but there were no 
specific time points in which the groups different. Additionally, there were no significant 
differences between plasma NEFA concentrations of EV versus EC animals (Fig. 4). 
Although we expected a rise in NEFAs with exercise compared to the sedentary controls, 
our results indicated no change between the groups. This is potentially due to the fact that 
any increase in mobilization of NEFAs may have been matched by oxidized in the 
working muscles, thereby maintaining plasma levels at a normal volume. Looking at the 
lipolytic activity of the adipose tissue further confirms that enhanced lipolysis is not 
occurring with the moderate to high dosage of corticosterone treatment (20mg/kg) in this 
time frame. If anything, we observed that exercise is impairing any lipolytic activity that 
may have been induced by corticosterone treatment at rest, as indicated by significantly 
reduced PLIN phosphorylation in the EC versus SC group. This change was not observed 
when analyzing HSL activity. When compared to the control exercisers (EV), there were 
no differences in phosphorylation of either PLIN or HSL, indicating that any effects of 
corticosterone may be masked with exercise. As expected, there was an effect of exercise 
compared to the sedentary vehicle group to increase lipolytic enzyme activity.  
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Consistently GCs are associated with an increase in hyperglycaemia. Chronic 
models of hypercortisolemia result in increased fasting blood glucose and insulin 
resistance. It has previously been reported that a 3-day treatment of dexamethasone 
(2mg/day) in humans results in a dramatic increase (55-110%) in glucagon secretion[163] 
and rodent models have determined that these adaptations are likely due to changes in 
alpha cell mass[79]. Once again, less data is available on the immediate effects of GCs, 
specifically with exercise. Our data demonstrated that short-term treatment with GCs had 
no effect on blood glucose, although there was an increase with exercise (Fig. 6.1). 
Plasma insulin was unaffected by corticosterone treatment and surprisingly also 
unaffected by exercise (Fig. 6.2). Normally, in rodents and in humans, insulin levels drop 
with prolonged exercise while counter-regulatory hormone levels rise [164,165]. In the 
sedentary groups, EC increased glucagon compared to EV, but no differences were 
observed in glucagon between the exercise groups. This data indicates that it is plausible 
that GCs increase blood glucose concentrations through inducing a rise in glucagon at 
rest (Fig. 6.3), but it is possible that our protocol did not allow for glucagon to stimulate 
and increase in blood glucose, and perhaps we would seen this increase if we increased 
our protocol to measure up to t = +120 minutes. According to our RER data, the SC at the 
end of the experiment appeared to be relying more heavily on FFA oxidation, so it is not 
likely that enhanced oxidation of the CHOs are responsible for the lack of changes 
observed in BG at rest. 
Taken all together, it is likely that corticosterone may induce immediate lipolytic 
actions at rest. Our data determined that corticosterone treated animals had more 
variability in RER when sedentary, potentially mediated through altered lipolytic enzyme 
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activity. It may also increase glycaemia, but these changes may take longer to occur, 
considering that plasma glucagon, but not blood glucose concentrations were increased. 
In an acute exercise state, it appears that there are no differences in lipolytic actions with 
GC treatment, considering that no differences were observed in oxidation after exercise 
between EV and EC and there was reduced PLIN activity in EC compared to SC. Further 
examination at additional time points would be beneficial to further understand the 
immediate actions of GCs.  
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FIGURES  
 
Figure 2; Plasma corticosterone content. White box indicates vehicle treatment, shaded 
boxes indicate corticosterone. The light grey box denotes the range of the pre-treatment 
mean ± standard deviation. Pre-treatment plasma samples were collected via saphenous 
vein, post-treatment were collected from the trunk blood. A main effect of corticosterone 
treatment (P<0.0001) and an interaction between treatment and activity were observed 
(p<0.0001). * indicates p = 0.0005. SV, n = 7; SC, n = 13; EV, n = 10; EC, n= 10.  
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Figure 3.0; Respiratory exchange ratio; hashed box indicates exercise period. Corticosterone 
animals are indicated with black symbols, white symbols indicate vehicle. A) RER in sedentary 
animals. There was a significant interaction between treatment and time (p = 0.0033), but no 
main effect of treatment. B) RER with exercise. No effect of treatment or interaction between 
treatment and time occurred, but there was a significant effect of time (p<0.0001). SV, n = 6, SC, 
n = 4, EV, n = 10, EC, n = 10.  
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Figure 4.0. Plasma Non-esterified fatty acid content. White box indicates vehicle 
treatment, shaded boxes indicate corticosterone. The light grey box denotes the range of 
the pre-treatment average ± standard deviation. Pre-treatment plasma samples were 
collected via saphenous vein, post-treatment were collected from the trunk blood under 
isoflurane. There were no significant effects of treatment or activity. SV, n = 7; SC, n = 
13; EV, n = 10; EC, n =10. 
 	
0.0
0.5
1.0
1.5
2.0
2.5
N
EF
A 
C
on
ce
nt
ra
tio
n 
(m
m
ol
/L
)
Vehicle
Corticosterone
Sedentary Exercise
		 52	
		Phosphorylated	hormone	sensitive	lipase	(~81	kDa)	 	 		Total	hormone	sensitive	lipase	(~81	kDa)		 	Beta-actin	(~42	kDa)	 	 			
Figure 5.1. Lipolytic enzyme measures; Hormone sensitive lipase (HSL) Activity. 
Lipolytic enzyme activities as measured by western blot. HSL activity was measured 
using a phosphorylated HSL antibody relative to total HSL in the peritoneal fat depot. 
White boxes indicate vehicle treatment, while shaded boxes indicate corticosterone. All 
samples are made relative to the sedentary control on the gel they were run on. There 
were no significant effects of treatment or activity. SV, n = 6; SC, n = 8; EV, n = 10; EC, 
n =10. 
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			Protein	Kinase	A	-substrate	indicator	(~65	kDa)	 	 		Perilipin	-	A	(~65	kDa)			 	 		Beta	Actin	(~42	kDa)	 	 		
Figure 5.2. Lipolytic enzyme measures; Perilipin Activity. Lipolytic enzyme activities 
as measured by western blot. Perilipin activity was measured using a phosphorylated 
PKA substrate indicator relative to total Perilipin in the peritoneal fat depot. White boxes 
indicate vehicle treatment, while shaded boxes indicate corticosterone. All samples are 
made relative to the sedentary control on the gel they were run on. SC was significantly 
different from EC (p = 0.047). SV, n = 6; SC, n = 8; EV, n = 10; EC, n =10. 
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Figure 6.1; Measures of Glycaemia - blood glucose concentrations. White box 
indicates vehicle treatment, shaded boxes indicate corticosterone. The light grey box 
denotes a normal blood glucose range, derived of the pre-treatment average ± standard 
deviation. Pre-treatment blood samples were measured during a blood draw from the 
saphenous vein and post-treatment were measured via tail-prick. There was significant 
effect of exercise, but not treatment (p<0.0001). SV, n = 7; SC, n = 13; EV, n = 7; EC, n 
= 9.  
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Figure 6.2. Measures of Glycaemia - plasma insulin concentrations. White box 
indicates vehicle treatment, shaded boxes indicate corticosterone. The light grey box 
denotes the range of the pre-treatment average ± standard deviation. Pre-treatment 
plasma samples were collected via saphenous vein, post-treatment were collected from 
the trunk blood under isoflurane. There were no significant effects of treatment or 
activity. SV, n = 7; SC, n = 13; EV, n = 8; EC, n = 8.  
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Figure 6.3. Measures of Glycaemia - plasma glucagon concentration. White box 
indicates vehicle treatment, shaded boxes indicate corticosterone. The light grey box 
denotes the range of the pre-treatment average ± standard deviation. Pre-treatment 
plasma samples were collected via saphenous vein, post-treatment were collected from 
the trunk blood under isoflurane. There was a significant effect of treatment (p = 0.0032), 
but not activity. SV was significantly lower than SC (p = 0.0226). SV, n = 7; SC, n = 13; 
EV, n = 8; EC, n = 8. .  
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5.0 SUMMARY, LIMITATIONS AND FUTURE DIRECTIONS  
Our findings indicate that it would be beneficial to take a closer examination at 
additional time points. For instance, tissue analysis was only taken one hour following 
treatment (t = +45 minutes), but further investigation is warranted at 25 minutes 
following injection to determine if there are any immediate anti-lipolytic actions 
occurring, as evidenced by the rise in RER, indicating a favouring of CHO oxidation. 
Additionally, it would be beneficial to carry out this study for another hour (total t = +120 
minutes), and see if the trends in RER would continue and any changes would occur in 
the phosphorylation of lipolytic enzymes or plasma NEFA levels.   
As well as this, no initial VO2Max test was conducted to determine the exact 
intensity for each rat. Instead, a running speed that had been previously used in other 
studies as a light to moderate intensity was chosen[166]. While moderate exercise does 
not usually alter blood glucose in healthy controls after just 45 minutes of light/moderate 
activity, intense exercise has been shown to increase glycaemia[167]. Considering that 
there was an effect of exercise to increase blood glucose in our data, it is possible that 
these animals were running at a higher intensity than anticipated. For this reason, a 
preliminary VO2Max test would be recommended if this model were to be repeated.  
When examining RER, there were some trends towards significant differences 
between the sedentary groups, such as at t = +10 minutes (p = 0.079). A possible reason 
we did not find significance is that the sedentary corticosterone group was underpowered 
(n=4) and the addition of more animals in this group would be beneficial. In Fig, S2.0, we 
examined the metabolic parameters of only the all animals that we had RER data. All of 
these graphs followed the same pattern as the graphs examining the full number of 
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subjects for these groups. However, with this smaller n, there was no main effect of 
corticosterone to influence plasma glucagon (Fig. S2.0C).   
While this was a successful model of examining the effects of a rapid increase in 
corticosterone in vivo, one of the most significant limitations of the study was that 
handling stress may have elicited a stress response in all animals, as indicated by a rise in 
corticosterone from the pre-treatment value (Fig. 2.0). These animals were not 
adrenalectomized and the i.p. injection of their treatment may have caused an increase in 
both corticosterone release, as well as epinephrine. Additionally, we could not prevent the 
rise in these hormones with exercise.  
One of the most primary markers of lipolysis is NEFA release. Although an 
ELISA kit examining plasma NEFA concentration was performed, this only indicates a 
static measurement in the plasma. In order to properly examine the dynamics of lipid 
metabolism, it would be ideal to measure the constant efflux of NEFAs. This may be does 
by utilizing stable isotopes labelled glycerol or NEFAs, or by measuring the aterio-
venous differences in NEFAs with a catheter[168]. Even with this method comes with 
some limitations; despite the accuracy of measuring flux, the aterio-venous difference can 
only be measured in subcutaneous tissue and could not provide information on omenal 
adipose lipolysis. In order to counter this, we used measures of oxidation (RER) and 
compared them with molecular measures of lipolysis (western blotting of lipolytic 
enzymes).  
Overall, our study suggests it is possible that 1 hour following corticosterone 
treatment may enhance lipolytic activity and NEFA oxidation. Contrary to many exercise 
physiology textbooks, it appears that further elevating GCs during exercise does not 
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appear to be mediating any effects on lipolysis. Further research at additional time points 
and various intensities would be beneficial to gain a better understanding of the 
immediate actions of GCs. 	 	
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7.0 APPENDIX  
 
 
Figure S1.0; Body weight in grams on day of experiment. Vehicle animals are expressed as 
white box, corticosterone treated animals expressed as shaded box. There was a significant effect 
of treatment (p = 0.03). SC weighed significantly less than EC (p = 0.004). SV; n = 7, SC; n = 
13, EV; n = 10, EC; n = 10. 
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Figure S2.0; Metabolic Data for all animals in which RER data was collected. Vehicle 
animals are expressed as white box, corticosterone treated animals. Data is represented as mean 
± standard deviation.  The light grey box denotes the range of the pre-treatment mean ± standard 
deviation. A) Plasma corticosterone content. Main effect of treatment (p = 0.0003). B) Plasma 
non-esterified fatty acid content. C) Plasma glucagon content. D) Blood glucose content. Main 
effect of activity (p<0.0001). E) Plasma insulin content. SV; n = 7, SC; n = 4, EV; n = 10, EC; n 
= 10. 
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Figure S3.0; Respiratory exchange ratio for exercising animals at all time points; hashed 
box indicates exercise period. Corticosterone animals are indicated with black symbols, white 
symbols indicate vehicle. Data points represent mean RER over 3 minutes with standard 
deviation. There was an effect of treatment (p = 0.0098), and an effect of time (p<0.0001), but no 
interaction. EV, n = 10, EC, n = 10.  	
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